Sun Pharma appoints Kirti Ganorkar as Managing Director

Mumbai, India, June 13, 2025: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) Sun Pharma today announced appointment of Kirti Ganorkar as the Managing Director to succeed Dilip Shanghvi, effective September 1, 2025, with the entire business and all functions reporting to him. This appointment is subject to approval of the shareholders at the upcoming Annual General Meeting.

Today’s announcement marks the culmination of a structured and forward-looking succession planning process at Sun Pharma, underscoring the organisation’s commitment to leadership continuity and strategic governance.

Brief profile of Kirti Ganorkar

Kirti Ganorkar has been heading India Business at Sun Pharma since June 2019. Under his leadership, the company’s India Business has grown consistently, further increasing its market share.

• Previously, Kirti has held various leadership roles across business development, marketing, M&A, new product introduction, project management, IP and litigation at Sun Pharma.

• Kirti played a key role in driving Sun Pharma’s foray into specialty by securing rights for innovative products such as Ilumya.

• Kirti led Sun Pharma’s entry into Japan and laid initial groundwork for the company’s entry into Europe. He supported the U.S. business with stewardship of several notable generic projects from concept to commercialisation.

Academics

Kirti a chemical engineer and MBA, joined Sun Pharma in 1996.

Kirti Ganorkar, Managing Director (Designate) of Sun Pharma stated, "It has been a profoundly rewarding journey to participate in the company’s transformation into a leading global pharmaceutical enterprise. Sun Pharma is at an exciting juncture with all its businesses well-positioned for growth. Building on the strong foundation laid by Mr. Shanghvi and ably supported by our global leadership team, I’m confident of continued success of the company.”

Leadership Commentary

Dilip Shanghvi, Chairman & Managing Director of Sun Pharma said, “Kirti has consistently demonstrated effective leadership managing diverse roles at Sun. I have a firm belief in his ability to lead the company into its next phase of growth and extend my best wishes for his success. Kirti’s elevation showcases our strong in-house talent pool, ensuring continuity of Sun’s core value systems.”

As Executive Chairman, Mr Shanghvi will continue to chair the Board. He will focus on strengthening Sun Pharma’s specialty portfolio and provide insights towards shaping company’s long-term strategy.

Aalok Shanghvi – Whole-time Director and Chief Operating Officer, has been additionally entrusted with the responsibility for the North America business wherein Rick will report to Aalok.

About Sun Pharmaceutical Industries Limited

Sun Pharma is the world’s leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma’s high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations.